MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Gabapentin GR™ for the treatment of postmenopausal hot flashes. Pending the standard 30-day FDA review period, the company expects to initiate a Phase 2 clinical trial in the second quarter of 2007.
